KRAS and malignant colon neoplasm: We observed strong selection for KRAS-12D over time, which was further enhanced by the EGF receptor inhibitor gefitinib, reflecting the clinical importance of KRAS-12D mutation as a resistance mechanism for anti-EGF receptor therapy in colon cancer (Fig. 4f).